About
Basic Data Updated:
15 days agoIntas Pharmaceuticals Limited, an Indian pharmaceutical company, has made a significant impact in the healthcare industry. With a strong focus on research and development, the company has diversified into various therapeutic areas, catering to the needs of patients worldwide. Through its commitment to quality and innovation, Intas has successfully ventured into international markets by exporting generic drugs and providing contract manufacturing services. As of March 31, 2019, Intas Pharmaceuticals Limited boasted 16 state-of-the-art manufacturing facilities, strategically located across the globe. These facilities include 11 in India, three in the UK, and one in Mexico. Each facility is equipped with cutting-edge technology and adheres to strict regulatory standards, ensuring the production of high-quality medicines. In fact, Intas' manufacturing facilities have received approvals from prestigious regulatory authorities such as the US Food and Drug Administration (USFDA), UK Medicines and Healthcare products Regulatory Agency (MHRA), Medicines Control Council (MCC) in South Africa, Therapeutic Goods Administration (TGA) in Australia, and Agência Nacional de Vigilância Sanitária (ANVISA) in Brazil.
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Website12224421
- Telephone12224421
- Email Address12224421
- Social Media12224421
| CIN/LLPIN/FCRN | U24231GJ1985PLC007866 |
| Company No. | 007866 |
| Company Classification | Public Limited Indian Non-Government Company |
| Incorporation Date | 31 May 1985 |
| Date of AGM | 31 Jul 2023 |
| Date of Balance Sheet | 31 Mar 2023 |
| Listing Status | Unlisted |
| ROC Code | Roc Ahmedabad |
Products or Services related to Intas Pharmaceuticals Limited
Hair Growth for Men
Probiotics
Facewash
Vitamins A-Z
Financials of Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 3.44% decrease. The company also saw a substantial fall in profitability, with a 17.74% decrease in profit. The company's net worth Soared by an impressive increase of 13.06%.
Corporate Structure
Unlock access to Intas Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
People in Intas Pharmaceuticals Limited
Unlock and access historical data on people associated with Intas Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Executive Team (5)
UC
Urmish Chudgar
Managing DirectorAppointment Date: 30-Sep-1996
Status: Current
BC
Binish Chudgar Managing DirectorAppointment Date: 31-May-1985
Status: Current
NC
Nimish Chudgar Managing DirectorAppointment Date: 31-May-1985
Status: Current
JS
Jayesh Shah CFOAppointment Date: 21-Mar-2023
Status: Current
MN
Manoj Nair Company SecretaryAppointment Date: 08-Jun-2007
Status: Current
Board Members(8)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 25 Jun 1999 | ₹750.00 Cr | Open |
Dena Bank Creation Date: 01 May 1998 | ₹4.50 Cr | Open |
Standard Chartered Bank Creation Date: 04 Sep 2017 | ₹184.62 Cr | Satisfied |
Deals i
Gain comprehensive insights into the Deals and Valuation data of Intas Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Intas Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alert
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Related Corporates (Common Directorship)
Tfs Business Advisors India Private Limited
Active
18 years 2 months Surender Kumar is a mutual person
One Advertising And Communication Services Limited
Active 22 years 9 months Jayesh Shah is a mutual person
Gebbs Healthcare Solutions Private Limited
Active 20 years 4 months Sanjay Kukreja is a mutual person
Astron Packaging Limited
Active 22 years 10 months Urmish Chudgar, Binish Chudgar and 1 more are mutual person
Recent activity within the organization
Annual General Meeting
Intas Pharmaceuticals Limited last Annual general meeting of members was held on 31 Jul 2023 as per latest MCA records.
31 Jul 2023Director Appointment
Archana Ravindrarai Dholakia was appointed as a Director was appointed as a Director on 14 Jun 2023 & has been associated with this company since 10 months 27 days .
14 Jun 2023Balance Sheet
Intas Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Ahmedabad.
31 Mar 2023Charges
A charge registered on 28 Dec 2016 via Charge ID 100072051 with Others was fully satisfied on 30 Nov 2021.
30 Nov 2021Charges
A charge registered on 28 Dec 2016 via Charge ID 100071690 with Others was fully satisfied on 04 Aug 2021.
04 Aug 2021
Recent News, Updates & Announcement
DongA ST completes BLA filing with FDA for Stelara biosimilar.KBR 05 Jan 2024
- Intas Pharma Launches Affordable Biosimilar Cancer Drug in India Competes with Roches Avastin.
Intas Pharma launches Bevacizumab a biosimilar drug for cancer treatment in India at a lower price This drug is similar to Avastin by Roche Biologic drugs are complex and hard to identify Intas will compete with other companies in the market Roche has tried to stop the approval of biosimilar drugs Intas says they followed the rules and will make the drug more accessible to patients.
ET Bureau 05 Oct 2017
- Aurobindo Pharma Intas in race for Teva8217s European assets Mint.
Aurobindo Pharma and Intas are vying for Teva Pharmas European assets that include oncology pain management and womens health divisions of the firm.
mint 16 Aug 2017
- ChrysCapital to sell stake in Intas Pharma Mint.
ChrysCapital is in talks to dilute 3 of its near 6 stake in Ahmedabadbased Intas Pharmaceuticals.
mint 11 Jan 2017
- ChrysCapital to sell stake in Intas Pharma.
Deal Street Asia 11 Jan 2017
Frequently asked questions
What is the Incorporation or founding date of Intas Pharmaceuticals Limited?
